Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program
- PMID: 23979954
- PMCID: PMC3790618
- DOI: 10.1210/jc.2013-1452
Lifestyle and metformin treatment favorably influence lipoprotein subfraction distribution in the Diabetes Prevention Program
Abstract
Context: Although intensive lifestyle change (ILS) and metformin reduce diabetes incidence in subjects with impaired glucose tolerance (IGT), their effects on lipoprotein subfractions have not been studied.
Objective: The objective of the study was to characterize the effects of ILS and metformin vs placebo interventions on lipoprotein subfractions in the Diabetes Prevention Program.
Design: This was a randomized clinical trial, testing the effects of ILS, metformin, and placebo on diabetes development in subjects with IGT.
Participants: Selected individuals with IGT randomized in the Diabetes Prevention Program participated in the study.
Interventions: Interventions included randomization to metformin 850 mg or placebo twice daily or ILS aimed at a 7% weight loss using a low-fat diet with increased physical activity.
Main outcome measures: Lipoprotein subfraction size, density, and concentration measured by magnetic resonance and density gradient ultracentrifugation at baseline and 1 year were measured.
Results: ILS decreased large and buoyant very low-density lipoprotein, small and dense low-density lipoprotein (LDL), and small high-density lipoprotein (HDL) and raised large HDL. Metformin modestly reduced small and dense LDL and raised small and large HDL. Change in insulin resistance largely accounted for the intervention-associated decreases in large very low-density lipoprotein, whereas changes in body mass index (BMI) and adiponectin were strongly associated with changes in LDL. Baseline and a change in adiponectin were related to change in large HDL, and BMI change associated with small HDL change. The effect of metformin to increase small HDL was independent of adiponectin, BMI, and insulin resistance.
Conclusion: ILS and metformin treatment have favorable effects on lipoprotein subfractions that are primarily mediated by intervention-related changes in insulin resistance, BMI, and adiponectin. Interventions that slow the development of diabetes may also retard the progression of atherosclerosis.
Trial registration: ClinicalTrials.gov NCT00004992.
Figures
Similar articles
-
Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program.Metabolism. 2016 May;65(5):764-775. doi: 10.1016/j.metabol.2015.11.011. Epub 2015 Dec 2. Metabolism. 2016. PMID: 27085783 Free PMC article. Clinical Trial.
-
The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program.Metabolism. 2013 Sep;62(9):1313-22. doi: 10.1016/j.metabol.2013.04.005. Epub 2013 May 6. Metabolism. 2013. PMID: 23660512 Free PMC article. Clinical Trial.
-
[Progress in the prevention of type 2 diabetes].Wien Klin Wochenschr. 2003 Nov 28;115(21-22):745-57. doi: 10.1007/BF03040499. Wien Klin Wochenschr. 2003. PMID: 14743578 Review. German.
-
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.Diabetes Care. 2004 Jan;27(1):41-6. doi: 10.2337/diacare.27.1.41. Diabetes Care. 2004. PMID: 14693964 Clinical Trial.
-
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].Invest Clin. 1997 Mar;38(1):39-52. Invest Clin. 1997. PMID: 9235072 Review. Spanish.
Cited by
-
Association of lipoprotein subfractions with incidence of type 2 diabetes among five U.S. Race and Ethnic groups: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) and Multi-Ethnic study of Atherosclerosis (MESA).Diabetes Res Clin Pract. 2023 Oct;204:110926. doi: 10.1016/j.diabres.2023.110926. Epub 2023 Sep 28. Diabetes Res Clin Pract. 2023. PMID: 37777016 Free PMC article.
-
Comparison of long-term effects of metformin on longevity between people with type 2 diabetes and matched non-diabetic controls.BMC Public Health. 2023 May 2;23(1):804. doi: 10.1186/s12889-023-15764-y. BMC Public Health. 2023. PMID: 37131166 Free PMC article.
-
Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease.Int J Mol Sci. 2023 Jan 13;24(2):1646. doi: 10.3390/ijms24021646. Int J Mol Sci. 2023. PMID: 36675160 Free PMC article. Review.
-
Correlations between the Changing Levels of Tissue Plasminogen Activator and Adiposity Following Exercise-Induced Weight Loss.Nutrients. 2022 Dec 4;14(23):5159. doi: 10.3390/nu14235159. Nutrients. 2022. PMID: 36501190 Free PMC article.
-
Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.J Thorac Cardiovasc Surg. 2022 Nov;164(5):1318-1326.e3. doi: 10.1016/j.jtcvs.2022.02.046. Epub 2022 Mar 10. J Thorac Cardiovasc Surg. 2022. PMID: 35469597 Free PMC article.
References
-
- Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003;52:453–462 - PubMed
-
- Mayer-Davis EJ, Vitolins MZ, Carmichael SL, et al. Validity and reproducibility of a food frequency interview in a multi-cultural epidemiology Study. Ann Epidemiol. 1999;9:314–324 - PubMed
-
- Kriska AM, Caspersen CJ. Introduction to the collection of physical activity questionnaires. Med Sci Sports Exerc. 1997;29:5–9 - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical